Evidence map›Paper›PMID 32350571›Full record

ArticleInflammation research : official journal of the European Histamine Research Society ... [et al.]2020

SARS-CoV-2 will continue to circulate in the human population: an opinion from the point of view of the virus-host relationship.

Volodymyr V Oberemok, Kateryna V Laikova, Kseniya A Yurchenko, Irina I Fomochkina, Anatolii V Kubyshkin

Open access · bronzeAbstract read
In one paragraph

Article in Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 45 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Coming Out of Nowhere: The Paradox of the Birth of Omicron.Journal of biomedical physics & engineering · 2022
    Article
  8. The role of IL-1 family of cytokines and receptors in pathogenesis of COVID-19.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2022
    Article
  9. Article
  10. Article
  11. Article
  12. How immunity from and interaction with seasonal coronaviruses can shape SARS-CoV-2 epidemiology.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. SARS-CoV-2 will continue to circulate in the human population: no worries with state-of-the-art research and dependably useful results.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2021
    Article
  18. Review
  19. Construction of SARS-CoV-2 Virus-Like Particles by Mammalian Expression System.Frontiers in bioengineering and biotechnology · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 2 countries.

Volodymyr V OberemokV.I. Vernadsky Crimean Federal University, Simferopol, Russia.
Kateryna V LaikovaV.I. Vernadsky Crimean Federal University, Simferopol, Russia.
Kseniya A YurchenkoV.I. Vernadsky Crimean Federal University, Simferopol, Russia.
Irina I FomochkinaV.I. Vernadsky Crimean Federal University, Simferopol, Russia.
Anatolii V KubyshkinV.I. Vernadsky Crimean Federal University, Simferopol, Russia. kubyshkin_av@mail.ru.ORCID http://orcid.org/0000-0002-1309-4005
Research Institute of Agriculture of Crimea · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

At the population level, the virus-host relationship is not set up to end with the complete elimination of either or both. Pathogen-resistant individuals will always remain in the host population. In turn, the virus can never completely eliminate the host population, because evolutionarily such an event is a dead end for the virus as an obligate intracellular parasite. A certain existential balance exists in the virus-host relationship. Against this backdrop, viral epidemics and pandemics only become manifest and egregious to human beings when tens and hundreds of thousands of people die and the question emerges what caused the high mortality peaks on the death chart. The answer seems clear; the emerging strain of the virus is new to the host population, and new mutations of the virus and natural selection will lead to a survival of only genetically resistant individuals in a host population. The dangers inherent to a novel virus are due to new features generally inthe molecular structure of proteins, which enable the virus to infect the cells of the host organism more intensively, dramatically challenging host immunity, and thus be transmitted more readily in the host population. In this article, we will concentrate on the facts currently available about severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which has caused COVID-19 (coronavirus disease 2019) pandemic and try to predict its development and consequences based on the virus-host relationship. In fact, only two scenarios will occur simultaneously in the very near future: people who are genetically resistant to the virus will get sick, recover, and develop immunity, while people who are sensitive to the virus will need drugs and vaccines, which will have to be researched and developed if they are to recover. If the pandemic does not stop, in a few decades it is anticipated that SARS-CoV-2 will become as safe as the four non-severe acute respiratory syndrome human coronaviruses (HCoV-NL63, HCoV-HKU1, HCoV-OC43, and HCoV-229E) currently circulating but causing low mortality in the human population.

Indexed as

Host-Pathogen InteractionsAngiotensin-Converting Enzyme 2AnimalsBetacoronavirusCoronavirus InfectionsCOVID-19COVID-19 Drug TreatmentCOVID-19 VaccinesDisease ResistanceHumansImmunityPandemicsPeptidyl-Dipeptidase APneumonia, ViralSARS-CoV-2Selection, GeneticACE2 protein, humanAngiotensin-Converting Enzyme 2COVID-19 VaccinesPeptidyl-Dipeptidase AViral VaccinesPandemicSARS-CoV-2Virus-host relationship system

Identifiers

PMID32350571
PMCPMC7190393
OpenAlexW3017431709

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.